Charles Rhyee
Stock Analyst at TD Cowen
(1.96)
# 3,108
Out of 5,072 analysts
64
Total ratings
40.91%
Success rate
-8.04%
Average return
Main Sectors:
Stocks Rated by Charles Rhyee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GDRX GoodRx Holdings | Maintains: Buy | $7 → $6 | $2.83 | +112.01% | 8 | Nov 10, 2025 | |
| CRL Charles River Laboratories International | Maintains: Buy | $205 → $197 | $178.94 | +10.09% | 6 | Nov 10, 2025 | |
| COR Cencora | Maintains: Buy | $350 → $400 | $368.53 | +8.54% | 1 | Nov 10, 2025 | |
| CI The Cigna Group | Maintains: Buy | $387 → $333 | $278.35 | +19.63% | 1 | Nov 4, 2025 | |
| CVS CVS Health | Maintains: Buy | $99 → $100 | $79.86 | +25.22% | 1 | Nov 3, 2025 | |
| CAH Cardinal Health | Maintains: Buy | $183 → $225 | $213.14 | +5.56% | 3 | Nov 3, 2025 | |
| OPCH Option Care Health | Maintains: Hold | $30 → $27 | $31.02 | -12.96% | 2 | Nov 3, 2025 | |
| IQV IQVIA Holdings | Downgrades: Hold | $206 → $215 | $231.80 | -7.25% | 2 | Nov 3, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Hold | $183 → $172 | $183.65 | -6.34% | 5 | Oct 24, 2025 | |
| MEDP Medpace Holdings | Maintains: Sell | $356 → $462 | $606.60 | -23.84% | 6 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $297 → $380 | $240.67 | +57.89% | 4 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $830 → $864 | $883.71 | -2.23% | 4 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $23 → $25 | $12.63 | +97.94% | 3 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $9 → $8 | $7.45 | +7.38% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $3.41 | +46.63% | 2 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $100 → $50 | $4.11 | +1,116.55% | 3 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $56 | $13.27 | +322.00% | 2 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $360 → $280 | $12.00 | +2,233.33% | 3 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $4.20 | +1,090.48% | 2 | Jun 21, 2022 |
GoodRx Holdings
Nov 10, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.83
Upside: +112.01%
Charles River Laboratories International
Nov 10, 2025
Maintains: Buy
Price Target: $205 → $197
Current: $178.94
Upside: +10.09%
Cencora
Nov 10, 2025
Maintains: Buy
Price Target: $350 → $400
Current: $368.53
Upside: +8.54%
The Cigna Group
Nov 4, 2025
Maintains: Buy
Price Target: $387 → $333
Current: $278.35
Upside: +19.63%
CVS Health
Nov 3, 2025
Maintains: Buy
Price Target: $99 → $100
Current: $79.86
Upside: +25.22%
Cardinal Health
Nov 3, 2025
Maintains: Buy
Price Target: $183 → $225
Current: $213.14
Upside: +5.56%
Option Care Health
Nov 3, 2025
Maintains: Hold
Price Target: $30 → $27
Current: $31.02
Upside: -12.96%
IQVIA Holdings
Nov 3, 2025
Downgrades: Hold
Price Target: $206 → $215
Current: $231.80
Upside: -7.25%
ICON Public Limited Company
Oct 24, 2025
Maintains: Hold
Price Target: $183 → $172
Current: $183.65
Upside: -6.34%
Medpace Holdings
Oct 24, 2025
Maintains: Sell
Price Target: $356 → $462
Current: $606.60
Upside: -23.84%
Oct 7, 2025
Upgrades: Buy
Price Target: $297 → $380
Current: $240.67
Upside: +57.89%
Sep 24, 2025
Maintains: Buy
Price Target: $830 → $864
Current: $883.71
Upside: -2.23%
Nov 11, 2024
Maintains: Hold
Price Target: $23 → $25
Current: $12.63
Upside: +97.94%
Oct 31, 2024
Maintains: Hold
Price Target: $9 → $8
Current: $7.45
Upside: +7.38%
May 3, 2023
Maintains: Outperform
Price Target: $4 → $5
Current: $3.41
Upside: +46.63%
Mar 23, 2023
Downgrades: Market Perform
Price Target: $100 → $50
Current: $4.11
Upside: +1,116.55%
Oct 20, 2022
Maintains: Outperform
Price Target: $70 → $56
Current: $13.27
Upside: +322.00%
Aug 16, 2022
Maintains: Outperform
Price Target: $360 → $280
Current: $12.00
Upside: +2,233.33%
Jun 21, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $4.20
Upside: +1,090.48%